Moreover, another result identified that anagliptin provides protection against vascular dysfunction in ECs triggered by hyperglycemia, and the action is mediated by the inhibition of NLR family, pyrin domain containing 3 (NLRP3) inflammasome activation that relies on the sirtuin 1 (SIRT1)-dependent pathway (10). Here, NLRP3 is linked to Hyperglycemia.